SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

FARMER, Paul et al. Community-based treatment of advanced HIV disease: introducing DOT-HAART (directly observed therapy with highly active antiretroviral therapy). Bull World Health Organ [online]. 2001, vol.79, n.12, pp. 1145-1151. ISSN 0042-9686.  http://dx.doi.org/10.1590/S0042-96862001001200011.

    1. Spector SA. Factors impacting on drug choices. Issues for developing countries. Annals of the New York Academy of Sciences, 2000, 918: 346–350.

    [ Links ]

    2. Cohen J. AIDS meeting. Companies, donors pledge to close gap in AIDS treatment. Science, 2000, 289: 368–369.

    [ Links ]

    3. Individual members of the Faculty of Harvard University. Consensus statement on antiretroviral treatment for AIDS in poor countries. Topics in HIV Medicine, 2001, 9: 14–26.

    [ Links ]

    4. The world factbook 2000. Central Intelligence Agency (accessed on 20 August 2001 at http://www.odci.gov/cia/publications/factbook/ha.html).

    [ Links ]

    5. Piot P. Global AIDS epidemic: time to turn the tide. Science, 2000, 288: 2176–2178.

    [ Links ]

    6. Bloom DE. Something to be done: treating HIV/AIDS. River Path Associates. Science, 2000, 288: 2171–2173.

    [ Links ]

    7. Farmer PE, Walton DA, Furin JJ. The changing face of AIDS: implications for policy and practice. In: Mayer K, Pizer H, eds. The emergence of AIDS: the impact on immunology, microbiology, and public health. Washington, DC, American Public Health Association, 2000.

    [ Links ]

    8. El Sony AI et al. Tuberculosis control in Sudan against seemingly insurmountable odds. International Journal of Tuberculosis and Lung Disease, 2000, 4: 657–664.

    [ Links ]

    9. Del Mistro A, Chieco Bianchi L. HPV-related neoplasias in HIV- infected individuals. European Journal of Cancer, 2000, 37: 1227–1235.

    [ Links ]

    10. Madhi SA et al. Increased disease burden and antibiotic resistance of bacteria causing severe community-acquired lower respiratory tract infections in human immunodeficiency virus type 1-infected children. Clinical Infectious Diseases, 2000, 31: 170–176.

    [ Links ]

    11. Sibanda A. A nation in pain: why the HIV/AIDS epidemic is out of control in Zimbabwe. International Journal of Health Services, 2000, 30: 717–738.

    [ Links ]

    12. Floyd K et al. Admission trends in a rural South African hospital during the early years of the HIV epidemic. JAMA, 1999, 282: 1087–1091.

    [ Links ]

    13. Low-Beer D, Stoneburner RL, Mukulu A. Empirical evidence for the severe but localized impact of AIDS on population structure. Nature Medicine, 1997, 3: 553–557.

    [ Links ]

    14. Farmer P. Social inequalities and emerging infectious diseases. Emerging Infectious Diseases, 1996, 4: 259–269.

    [ Links ]

    15. Accorsi S et al. Impact of insecurity, the AIDS epidemic, and poverty on population health: disease patterns and trends in Northern Uganda. American Journal of Tropical Medicine and Hygiene, 2001, 64: 214–221.

    [ Links ]

    16. Butler C. HIV and AIDS, poverty, and causation. Lancet, 2000, 356: 1445–1446.

    [ Links ]

    17. Basu S, Mate K, Farmer, PE. Debt and poverty turn a disease into an epidemic. Nature, 2000, 407: 13.

    [ Links ]

    18. Kandela P. Child prostitution and the spread of AIDS. Lancet, 2000, 356: 1991.

    [ Links ]

    19. Beyrer C. Burma and Cambodia: human rights, social disruption, and the spread of HIV/AIDS. Health and Human Rights, 1998, 2: 84–97.

    [ Links ]

    20. Farmer P, Connors M, Simmons J, eds. Women, poverty, and AIDS: sex, drugs, and structural violence. Monroe, ME, Common Courage Press, 1996.

    [ Links ]

    21. O'Leary A, Martins P. Structural factors affecting women's HIV risk: a life-course example. AIDS, 2000, 14 (Suppl. 1): S68–S72.

    [ Links ]

    22. Luo C. Achievable standard of care in low-resource settings. Annals of the New York Academy of Sciences, 2000, 918: 179–187.

    [ Links ]

    23. Wilkinson D, Floyd K, Gilks CF. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa. South African Medical Journal, 2000, 90: 794–798.

    [ Links ]

    24. Dayton JM, Merson MH. Global dimensions of the AIDS epidemic: implications for prevention and care. Infectious Disease Clinics of North America, 14: 791–808.

    [ Links ]

    25. Rogers MF, Stockton PL. Organizational approaches to the HIV/AIDS crisis. Annals of the New York Academy of Sciences, 2000, 918: 188–194.

    [ Links ]

    26. Kapiga SH et al. Predictors of AIDS knowledge, condom use and high risk sexual behaviour among women in Dar-es-Salaam, Tanzania. International Journal of STD & AIDS, 1995, 6: 175–183.

    [ Links ]

    27. Takyi BK. AIDS-related knowledge and risks and contraceptive practices in Ghana: the early 1990s. African Journal of Reproductive Health, 2000, 4: 13–27.

    [ Links ]

    28. Mayaud P, Hawkes S, Mabey D. Advances in control of sexually transmitted disease in developing countries. Lancet, 1998, 351 (Suppl. 3): 29–32.

    [ Links ]

    29. HIV/AIDS surveillance report. Vol. 11, No. 2. Atlanta, GA, Centers for Disease Control and Prevention, 1999.

    [ Links ]

    30. Attaran A, Sachs J. Defining and refining international donor support for combating the AIDS pandemic. Lancet, 2001, 357: 57–61.

    [ Links ]

    31. Donnelly J. Policy on AIDS in Africa debated, leaders say prevention should be the focus. The Boston Globe, 7 April 2001.

    [ Links ]

    32. Costs of antiretroviral drugs in Brazil (1996–2000). Ministry of Health, Brazil, 2000 (accessed on 7 November 2001 at http://www.aids.gov.br/assistencia/costs_antiretroviral_drugs_brazil.htm).

    [ Links ]

    33. Kahn J. Rich nations consider fund of billions to fight AIDS. New York Times, 29 April 2001: 10.

    [ Links ]

    34. Colebunders R et al. Impact of new developments in antiretroviral treatment on AIDS prevention and care in resource- poor countries. AIDS Patient Care and STDs, 2000, 14: 251–257.

    [ Links ]

    35. De Cock KM. Tuberculosis control in resource-poor settings with high rates of HIV infection. American Journal of Public Health, 1996, 86 (8 Part 1): 1071–1073.

    [ Links ]

    36. Report on the global HIV/AIDS epidemic, June 2000. Geneva, UNAIDS, 2000 (unpublished document UNAIDS/00.13E).

    [ Links ]

    37. Pape J, Johnson WD. AIDS in Haiti: 1982–1992.Clinical Infectious Diseases, 1993, 17 (Suppl. 2): S341–S345.

    [ Links ]

    38. Chaisson RE, Coberly JS, De Cock KM. DOTS and drug resistance: a silver lining to a darkening cloud. International Journal of Tuberculosis and Lung Disease, 1999, 3: 1–3.

    [ Links ]

    39. Farmer PE. Letter from Haiti. AIDS Clinical Care, 1997, 9: 83–85.

    [ Links ]

    40. Farmer PE et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet, 2001, 358: 404–409.

    [ Links ]

    41. Farmer PE, Walton DA. Condoms, coups, and the ideology of prevention: facing failure in rural Haiti. In: Keenan J, ed. Catholic ethicists in HIV/AIDS prevention. Maryknoll, NY, Orbis Books, 2000.

    [ Links ]

    42. Lockman S et al. Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population- based prospective study of 301 pulmonary tuberculosis patients. Journal of Clinical Microbiology, 2001, 39: 1042–1047.

    [ Links ]

    43. Paterson DL et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 2000, 133: 21–30.

    [ Links ]

    44. Brouwer CN et al. Psychosocial and economic aspects of HIV/AIDS and counselling of caretakers of HIV-infected children in Uganda. AIDS Care, 2000, 12: 535540.

    [ Links ]

    45. McNeil DG. Selling cheap `generic' drugs, India's copycats irk industry. New York Times, 1 December 2000: 1(A).

    [ Links ]

    46. Gellman B. An unusual calculus of life and death; as millions perished in pandemic, firms debated access to drugs; players in the debate over drug availability and pricing. Washington Post, 16 December 2000, Section A: 1.

    [ Links ]

    47. Freedberg KA et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. New England Journal of Medicine, 2000, 344: 824–831.

    [ Links ]

    48. Pérez-Casas P et al. HIV/AIDS medicines pricing report. Setting objectives: is there a political will? Access to Essential Medicines Campaign, Médecins Sans Frontières, 6 July 2000.

    [ Links ]

    49. Rifampicin or ethambutol in the routine treatment of tuberculosis. British Medical Journal, 1973, 4: 568 [editorial].

    [ Links ]

    50. Gupta R et al. Responding to market failures in tuberculosis control. Science, 2001, 293: 1049–1051.

    [ Links ]

    51. Farmer PE. The major infectious diseases in the world — to treat or not to treat? New England Journal of Medicine, 2001, 345: 208–210.

    [ Links ]